YAP1 and lung adenocarcinoma: [9] Instead of focusing on EGFR itself, here we demonstrate YAP1, an important molecule downstream of EGFR, can act as a potential alternative therapeutic target for EGFR-dependent lung adenocarcinomas, including those with T790M.